Equities Analysts Set Expectations for DVAX FY2024 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Stock analysts at William Blair lifted their FY2024 earnings per share (EPS) estimates for shares of Dynavax Technologies in a research note issued on Thursday, November 7th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $0.15 for the year, up from their previous forecast of $0.12. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.16 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.11 EPS and FY2025 earnings at $0.27 EPS.

Several other equities analysts have also recently weighed in on DVAX. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Friday.

Dynavax Technologies Stock Up 8.2 %

NASDAQ:DVAX opened at $13.01 on Monday. The stock has a 50-day simple moving average of $11.16 and a 200 day simple moving average of $11.24. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $15.01. The company has a market cap of $1.70 billion, a PE ratio of 118.28 and a beta of 1.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18.

Institutional Investors Weigh In On Dynavax Technologies

Several large investors have recently made changes to their positions in the stock. GAMMA Investing LLC raised its position in Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 1,685 shares in the last quarter. US Bancorp DE raised its holdings in shares of Dynavax Technologies by 291.4% in the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new stake in Dynavax Technologies in the 3rd quarter valued at about $45,000. Nisa Investment Advisors LLC grew its holdings in Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 1,679 shares during the period. Finally, Algert Global LLC acquired a new position in Dynavax Technologies during the second quarter worth approximately $140,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.